Trial · NCT00412542

Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas

NCT00412542, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2012-02-28

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas. Trials, record NCT00412542. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00412542

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas
NCT number: NCT00412542
Status: Completed
Phases: Phase 2
Enrollment: 78 participants, actual
Lead sponsor: M.D. Anderson Cancer Center
Conditions: Glioblastoma Multiforme, Glioma
Interventions: Thalidomide, CPT-11, MRI Scan, Quantitative Sensory Tests (QST)
First posted: 2006-12-18
Last updated: 2012-02-28
Results first posted: 2012-02-28

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants Progression Free at 6 Months With Malignant Gliomas	6 Months	Progression-free Survival (PFS) measured as number of participants that are alive and progression-free at 6 months.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants Progression Free at 6 Months With Malignant Gliomas	6 Months	7 participants enrolled were not evaluated as they were evaluable for toxicity only (not having completed the first cycle/clinical decline/etc.).	participants	NUMBER

Source ClinicalTrials.gov

Results by group1

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Participants Progression Free at 6 Months With Malignant Gliomas	Participants With Recurrent Malignant Gliomas		24		participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Glioblastoma Multiforme: Thalidomide + CPT-11	33
Overall Study	STARTED	Anaplastic Gliomas: Thalidomide + CPT-11	45
Overall Study	COMPLETED	Glioblastoma Multiforme: Thalidomide + CPT-11	33
Overall Study	COMPLETED	Anaplastic Gliomas: Thalidomide + CPT-11	42
Overall Study	NOT COMPLETED	Glioblastoma Multiforme: Thalidomide + CPT-11	0
Overall Study	NOT COMPLETED	Anaplastic Gliomas: Thalidomide + CPT-11	3

Source ClinicalTrials.gov

Adverse events119

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abdominal cramping	Gastrointestinal disorders	Patients With Recurrent Malignant Gliomas	9	75	18
other	Acne	Skin and subcutaneous tissue disorders	Patients With Recurrent Malignant Gliomas	12	75	17
other	Alkaline Phosphatase increased	Investigations	Patients With Recurrent Malignant Gliomas	11	75	18
other	Allergic rhinitis	Respiratory, thoracic and mediastinal disorders	Patients With Recurrent Malignant Gliomas	11	75	16
other	Alopecia	Skin and subcutaneous tissue disorders	Patients With Recurrent Malignant Gliomas	13	75	13
other	ALT increased	Investigations	Patients With Recurrent Malignant Gliomas	17	75	40
other	Anemia	Blood and lymphatic system disorders	Patients With Recurrent Malignant Gliomas	5	75	11
other	Anorexia	Gastrointestinal disorders	Patients With Recurrent Malignant Gliomas	22	75	25
other	AST elevated	Investigations	Patients With Recurrent Malignant Gliomas	12	75	19
other	Ataxia	Nervous system disorders	Patients With Recurrent Malignant Gliomas	6	75	9

1 to 10 of 119Source ClinicalTrials.gov

See all 119 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Patients With Recurrent Malignant Gliomas
Total, other adverse events	Patients With Recurrent Malignant Gliomas	65	75
Total, serious adverse events	Patients With Recurrent Malignant Gliomas	35	75

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00412542

GET https://conductscience.org/api/trials/v1/NCT00412542/events?page=2

API reference For AI assistants